N-Boc-溴乙胺 | 39684-80-5

• 物质功能分类: 有机原料 - 氨基化合物 - 无环单胺、多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-Boc-溴乙胺
• 中文别名: 2-(叔丁氧基羰基-氨基)-溴乙烷；2-(Boc-氨基)乙基溴；N-(2-溴乙基)氨基甲酸叔丁酯；2-(叔丁氧羰基氨基)乙基溴；2-(BOC-氨基)溴乙烷；N-叔丁氧羰基-溴乙胺；叔丁基(2-溴乙基)氨基甲酸酯
• 英文名称: 2-(tert-butoxycarbonylamino)ethyl bromide
• 英文别名: tert-butyl (2-bromoethyl)carbamate；tert-butyl N-(2-bromoethyl)carbamate；2-(boc-amino)ethyl bromide；N-Boc-bromoethylamine；N-Boc-2-bromoethylamine；(2-bromoethyl)carbamic acid tert-butyl ester；N-(tert-butoxycarbonyl)-2-bromoethylamine；N-tert-butoxycarbonylbromoethylamine；2-(boc-amino)bromoethane；Boc-bromoethylamine
• CAS: 39684-80-5
• 化学式: C₇H₁₄BrNO₂
• mdl: MFCD02683428
• 分子量: 224.098
• InChiKey: TZRQZPMQUXEZMC-UHFFFAOYSA-N

物化性质

• 熔点：
  30-32 °C(lit.)
• 沸点：
  262.3±23.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)
• 溶解度：
  易溶于可溶于氯仿、二氯甲烷和乙酸乙酯。
• 稳定性/保质期：
  在常规情况下不会分解，也没有危险的化学反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2924199090
• 危险品运输编号：
  NONH for all modes of transport
• 危险标志：
  GHS07
• 危险性描述：
  H302,H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 包装等级：
  III
• 危险类别：
  8
• 储存条件：
  密封、阴凉、干燥保存

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-(Boc-amino)ethyl bromide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 39684-80-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22, R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : tert-Butyl N-(2-bromoethyl)carbamate
N-Boc-2-bromoethyl-amine
Formula : C7H14BrNO2
Molecular Weight : 224,10 g/mol
CAS-No. : 39684-80-5
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
tert-(Butyl-N-(2-bromoethyl)carbamate
CAS-No. 39684-80-5 Acute Tox. 4; Skin Irrit. 2; Eye <= 100 %
Irrit. 2; STOT SE 3; H302,
H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
tert-(Butyl-N-(2-bromoethyl)carbamate
CAS-No. 39684-80-5 Xn, R22 - R36/37/38 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 30 - 32 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,00
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
acids, Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with
an afterburner and scrubber. Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

N-Boc-溴乙胺是一种有机中间体，可通过溴乙胺与Boc酸酐反应制备，常用的碱有碳酸氢钠、三乙胺或氢氧化钠。

用途

N-Boc-溴乙胺作为胺类化合物，可用作有机中间体。

制备

将20.5克(0.1摩尔)的溴乙胺溴酸盐溶解在80毫升四氢呋喃中，依次加入10.08克(0.12摩尔)碳酸氢钠和50毫升水。在室温下搅拌的同时，滴加21.80克(0.1摩尔)的二碳酸二叔丁酯，滴加完毕后继续反应4-10小时。反应完成后，减压蒸馏除去溶剂，并用乙酸乙酯萃取三次（每次50毫升），有机相再用50毫升饱和食盐水洗涤一次。干燥后得到21.84克无色油状液体，收率高达97.5%。

反应信息

• 作为反应物：
  描述：

  N-Boc-溴乙胺 在 盐酸 、 potassium carbonate 、 sodium nitrite 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  [EN] PYRAZOL-3-ONES THAT ACTIVATE PRO-APOPTOTIC BAX
  [FR] PYRAZOL-3-ONES QUI ACTIVENT LE BAX PRO-APOPTOTIQUE

  摘要：

  公开号：

  WO2013055949A3
• 作为产物：
  描述：

  2-({[(2-甲基-2-丙基)氧基]羰基}氨基)乙基甲烷磺酸酯 在 lithium bromide 作用下， 以 四氢呋喃 为溶剂， 以96%的产率得到N-Boc-溴乙胺
  参考文献：
  名称：

  Novel compounds and compositions for treating diseases asociated with protease activity

  摘要：

  描述了用于预防和治疗由肥大细胞介导的炎症性疾病的新化合物、组合物和方法。这些化合物、组合物和方法对预防和治疗与呼吸道相关的炎症性疾病（如哮喘和过敏性鼻炎）以及其他类型的免疫介导性炎症性疾病（如类风湿关节炎、结膜炎和炎症性肠病、各种皮肤病症以及某些病毒性疾病）有效。这些化合物包括对肥大细胞蛋白酶组胺酶的有效和选择性抑制剂。用于治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂，以及包含这些制剂的装置。

  公开号：

  US20010053779A1
• 作为试剂：
  描述：

  N-重氮基氨基甲酸叔-丁基酯 、 三乙胺 、 2-溴乙胺氢溴酸盐 在 乙醚 、 N-Boc-溴乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-Boc-溴乙胺
  参考文献：
  名称：

  Cephalosporins having (.alpha.-etherified oximino)acylamido groups at

  摘要：

  该发明提供了一种新型抗生素化合物，即7-β-酰胺基头孢-3-乙烯-4-羧酸及其非毒性衍生物，其特征在于酰胺基具有以下结构：##EQU1## 其中R是氢原子或有机基团，R.sup.a是通过碳原子与氧原子连接的醚化一价有机基团。这些化合物是同构体或存在至少75％的同构体混合物。这些抗生素化合物具有高抗菌活性，可对一系列革兰氏阳性和革兰氏阴性微生物产生高度的稳定性，其尤其对各种革兰氏阴性微生物产生的β-内酰胺酶具有高度的稳定性。该发明还涉及该化合物的给药。

  公开号：

  US03971778A1

文献信息

• [EN] BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS<br/>[FR] COMPOSÉS BENZAMIDE OU BENZAMINE À UTILISER EN TANT QU'ANTICANCÉREUX POUR LE TRAITEMENT DE CANCERS HUMAINS
  申请人：UNIV TEXAS

  公开号：WO2017007634A1

  公开（公告）日：2017-01-12

  The described invention provides small molecule anti-cancer compounds for treating tumors that respond to cholesterol biosynthesis inhibition. The compounds selectively inhibit the cholesterol biosynthetic pathway in tumor-derived cancer cells, but do not affect normally dividing cells.

  所描述的发明提供了用于治疗对胆固醇生物合成抑制作出反应的肿瘤的小分子抗癌化合物。这些化合物选择性地抑制肿瘤来源的癌细胞中的胆固醇生物合成途径，但不影响正常分裂的细胞。
• Synthesis and Characterization of Enzymatically Biodegradable PEG and Peptide-Based Hydrogels Prepared by Click Chemistry
  作者：Maarten van Dijk、Cornelus F. van Nostrum、Wim E. Hennink、Dirk T. S. Rijkers、Rob M. J. Liskamp

  DOI：10.1021/bm1002637

  日期：2010.6.14

  Herein we describe the synthesis and rheological characterization of a series of enzymatically sensitive PEG and peptide-based hydrogels by the Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction. The hydrogels were synthesized by a combination of alkyne-functionalized star-shaped PEG molecules (two 4-armed PEGs with Mw 10 and 20 kDa, respectively, and one 8-armed PEG of 20 kDa) and the protease-sensitive

  在这里，我们描述了通过Cu（I）催化的1,3-偶极环加成反应，合成了一系列酶敏性PEG和基于肽的水凝胶，并对其进行了流变学表征。水凝胶是由炔官能化的星形PEG分子的组合合成的（具有两个4武装的PEG中号瓦特分别为10和20kDa，和一个8武装PEG 20kDa的的）和蛋白酶敏感双叠氮肽，N α - （叠氮基） - d -丙氨酰苯丙氨酰lysyl-（2-叠氮基乙基） -酰胺（6中的CuSO的存在下）4和抗坏血酸钠水溶液。溶胀率和储能模量（G可以通过几个参数，例如水凝胶的初始固体含量，PEG衍生物的分子量和PEG分子的结构（4臂对8臂的PEG衍生物）来定制水凝胶的′′）。肽序列d -Ala-Phe-Lys对蛋白酶纤溶酶和胰蛋白酶敏感，使水凝胶可生物降解。
• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• LTA4H modulators and uses thereof
  申请人：Barchuk William T.

  公开号：US20080194630A1

  公开（公告）日：2008-08-14

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  白三烯A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的方法。
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。